Impact of the use of autologous stem cell transplantation at first relapse both in naïve and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study

Haematologica

Volumn 96, Issue 8, 2011, Pages 1128-1135

  le Gouill, Steven ^a   de Guibert, Sophie ^b   Planche, Lucie ^a   Brice, Pauline ^c   Dupuis, Jehan ^d   Cartron, Guillaume ^e   van Hoof, Achiel ^f   Casasnovas, Olivier ^f   Gyan, Emmanuel ^g   Tilly, Hervé ^h   Fruchart, Christophe ⁱ   Deconinck, Eric ^j,k   Fitoussi, Olivier ^l   Gastaud, Lauris ^m   Delwail, Vincent ⁿ   Gabarre, Jean ^o   Gressin, Rémy ^p   Blanc, Michel ^q   Foussard, Charles ^r   Salles, Gilles ^s  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

^f Centre Henri Becquerel ^*

^g UNIVERSITY HOSPITAL OF TOURS   (France)

^h CENTRE HENRI BECQUEREL   (France)

ⁱ CENTRE FRANÇOIS BACLESSE   (France)

^j INSERM   (France)

^k UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^l Polyclinique de Bordeaux Nord   (France)

^m Centre Antoine   (France)

ⁿ POITIERS UNIVERSITY HOSPITAL   (France)

^o PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^p GRENOBLE UNIVERSITY HOSPITAL   (France)

^q CENTRE HOSPITALIER DE CHAMBÉRY   (France)

^r ANGERS UNIVERSITY HOSPITAL   (France)

^s UNIVERSITÉ LYON 1   (France)

more..

Author keywords

Autologous stem cell transplantation; Follicular lymphoma; Rituximab

Indexed keywords

ALPHA2A INTERFERON; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; TENIPOSIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; EVENT FREE SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; RECURRENCE; RISK FACTORS; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 79961122635     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.030320     Document Type: Article

References (20)

1. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006;24(10):1582-9.
2. st century. Arch Intern Med. 2008;168(5):469-76.
3. Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, et al. East German Study Group Hematology and Oncology Study. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25(15):1986-92.
4. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725-32.
5. Marcus R, Imrie K, Solal-Celigny P, Cata-lano JV, Dmoszynska A, Raposo JC, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26(28):4579-86.
6. Salles G, Mounier N, de Guibert S, Morsch-hauser F, Doyen C, Rossi JF, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008;112(13):4824-31.
7. Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000;18(17):3135-43.
8. Johnston A, Bouafia-Sauvy F, Broussais-Guillaumot F, Michallet AS, Traullé C, Salles G, et al. Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study. Leuk Lymphoma. 2010; 51(3):399-405.
9. Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC, et al. Longterm follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 1999; 94(10): 3325-33.
10. Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J, et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol. 2007;25(18):2554-9.
11. Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantationin untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood. 2006;108(8):2540-4.
12. Ladetto M, Corradini P, Vallet S, Benedetti F, Vitolo U, Martelli M, et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood. 2002; 100(5):1559-65.
13. Sebban C, Brice P, Delarue R, Haioun C, Souleau B, Mounier N, et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol. 2008;26(21):3614-20.
14. Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson HE, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21(21):3918-27.
15. Deconinck E, Foussard C, Milpied N, Bertrand P, Michenet P, Cornillet-LeFebvre P, et al; GOELAMS. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood. 2005;105(10):3817-23.
16. Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, et al; Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL). Prospective, multicenter randomized GITMO/IIL trial comparing intensive (RHDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008;111(8):4004-13.
17. Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M, et al; German Low-Grade Lymphoma Study Group. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood. 2004;104(9):2667-74.
18. Gyan E, Foussard C, Bertrand P, Michenet P, Le Gouill S, Berthou C, et al; Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang (GOELAMS). High-dose therapy followed by autologous purged stem cell transplantation and doxorubicinbased chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood. 2009;113(5):995-1001.
19. Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, Wandt H, et al; German Low Grade Lymphoma Study Group (GLSG). Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108(13):4003-8.
20. van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108(10):3295-301.